another 90m shares issued at .3c, page-11

Went thru their annual reports and notice the following:

1. Company had lost (or invest) 68M in past 10 years.
2. wheezometer was completed in 2009. It got all the approvals yet minimal sales.
4. Burning rate was outrageous (1.5-2M per quarter!!!)

IMHO, such team should be "toasted". Just wonder how could the BOD kept such lousy team for so long. This company should file bankruptcy.

wheezometer must be promising or F500 companies wouldn't be interested. However there must be some obstacles preventing it from taking off.

Obviously, the old team couldn't figure out how to solve this puzzle. May be the nutty professor was part of the problem.

In past 10 months, the following things had been occurred:

1. New President
2. New BOD
3. New CEO and new team
4. Nutty professor was gone
5. ADR in US via OTC market
6. Huge cost-reduction
7. New vision, new product plan
8. Raise 4.3M fund

Obviously, old KSX had been wiped out. ISN should be considered as re-start-up. The fact is: ISN team now has 4.3M cash. The money will keep the boat floating and moving forward for another 18 to 24 months.

Let's assume that this new team is not stupid, with 4MM on hand, they have the freedom to wipe the whole product line out and develop something new. That's exactly what had happened. Why do they still keep Wheezometer but not the Wholter? This move is telling us that wheezometer do have a future.

Secondly, the vision has been narrowed from body acoustics to asthma management. A clearer marketing statement is posted: asthma management is a big arena. Wheezing, on the other hand, is indirect and narrow. Peak flow meter has been around for 50 years. All doctors, from professors to students, from Europe to Africa, ONLY know peak flow meter. Educating the entire global doctor population is a Mission Impossible $$$$. Pharma industry takes billions to promote new medication worldwide. ISN is simply too small for such game.

Asthma management on the other hand is a soft target. No paradigm shift equal better acceptance from those mighty doctors. The market will be even bigger if the app could support peak flow meter.

Besides, why not asking asthma patients to take both peak flow meter and wheezometer tests. There is no conflict anyway.

Given a great vision (10B) plus 4MM on hand plus track record (CEO, BOD and the team), it is making sense to invest as a "start-up", IMHO.